Endometriosis is a distressing disease, and difficult to treat. Even though it is so common, we still don`t know what causes it, and most medications just provide temporary relief. Development and maintenance of endometriotic implants depends on their invasive property and angiogenic potential. Inhibitors of angiogenesis effectively interfere with the maintenance and growth of endometriosis by inhibiting angiogenesis. In vitro studies have shown that dopamine agonists inhibit angiogenesis by reducing levels of VEGF. Small studies have shown their role in endometriosis but further studies especially well- designed RCTs are needed before these novel agents be introduced into clinical stream.